Pharma BD teams subscribe to curated deal flow — never raw databases. Biotech founders engage success-only — no subscriptions, no platform. The intelligence layer is our moat. The outcomes are yours.
Pick your track
JCA-aware shortlists. Conference BD. 12-month retainers calibrated to your geography.
Pharma engagementPharma-grade positioning + EU JCA + US AMCP readiness. Success-only fee.
Biotech engagementBiotech Assets Indexed
BD Contacts Mapped
Biotech Companies
Platform Technologies
Why "Living"?
Every other partnering platform gives you a snapshot. A directory frozen in time. ForesightRx is continuously updated from the ground — every conference, every meeting, every qualified conversation feeds the intelligence engine. In real time.
We attend 12+ global conferences annually. We meet the founders. We see the data rooms. We assess the science. No other platform does this.
Every qualified biotech asset is indexed by therapeutic area, stage, modality, geography, and deal readiness. Our AI maps it against pharma BD theses automatically.
We don't just match — we introduce, moderate, and facilitate. CDAs, NCD exchange, meeting prep, follow-ups. We stay in the loop until the deal is done.
The Three Pillars
Partnering intelligence is necessary. It is not sufficient. EU JCA and US AMCP / payer-value readiness decide whether a licensing deal becomes a commercial success — and we work both lenses into every engagement.
AI-scored outreach to the pharma buyers most likely to care. 2,750+ mapped BD contacts. Buyer-specific shortlists tuned to each pharma in-licensor's deck.
Joint Clinical Assessment in scope since January 2025 for oncology & ATMPs. PICO mapping, comparator landscape, ITC feasibility, evidence-gap analysis.
AMCP-format dossier, ICER preparedness, RWE strategy, budget-impact modeling, payer objection mapping. Pharma-grade rigour from the MarksMan team.
The Problem
Assets scattered across 10,000+ biotechs in 45+ markets. No single layer connects them to pharma capital.
Fly to 12 conferences. Sit through 40 meetings. Walk away with 3 leads. $615K+ annual BD cost — most of it wasted.
Deals still happen through who-you-know. Great science dies unfunded because the right buyer never sees it.
12-18 month deal cycles. Static databases, cold outreach, slow diligence. Both sides lose time and money.
We are fixing this.
Building the intelligence infrastructure that connects biotech innovation to pharma capital — globally, intelligently, and fast.
Three Audiences. One Engine.
Pharma BD subscribes to curated intelligence. Biotech founders engage success-only. Investors get a window into the asset flow they could never see otherwise. None of them log into our system — that's the point.
Subscribe to outcomes
Curated, continuously updated deal flow aligned to your BD thesis. You receive prioritized assets, deal benchmarks, and warm introductions — never raw data, never platform access.
Pay only on success
Get your asset in front of the right pharma buyers without expensive conference travel or giving away your data. Zero subscription. We earn only when your deal closes.
See the flow before the deal
The earliest signal in biopharma asset flow — what's being shopped, what's being licensed, who's on the other side of the table. A live read on the deal layer no public data covers.
Conference Intelligence — Next 3 Upcoming
While others scrape press releases, we are on the ground. Every conference we attend feeds fresh, qualified intelligence into the platform.
Stockholm, Sweden | Oct 2026
300+ assets expected
Europe | Mar 2027
Early pipeline focus
The Intelligence Layer
Not another database. A living deal enablement engine that combines AI-powered intelligence with human expertise from the world's top partnering conferences.
Our intelligence engine maps biotech assets against pharma BD theses using therapeutic area, clinical stage, modality, and geography — continuously updated from every conference we attend.
Oncology
312
Neurology
184
Immunology
147
Rare Disease
96
Cardiology
73
Metabolic
68
Deep networks across China, India, APAC, and global pharma. CDA orchestration, NCD exchange, warm introductions — end-to-end from first signal to signed deal.
The Deal Pathway
Share your BD thesis, therapeutic focus, and deal goals.
At conferences worldwide, we meet founders, assess science, and qualify assets.
Our engine surfaces the best fits. Our team adds context and judgment.
We position, reach out, facilitate NCD exchange, and manage CDAs.
Meeting prep, due diligence support, and facilitation until the deal is done.
Why ForesightRx
1,650+ biotechs, 3,900+ assets, 2,750+ pharma contacts, 3 years of pharma reply data. Pharma can't self-serve this; building it requires multi-year relationships and conference presence.
12+ conferences a year. We meet the founders, assess the science, and build relationships others can't replicate from a desk.
Every recommendation is human-qualified. AI augmented, expert-directed. Curated insight, not raw data.
Deep networks across China, India, APAC, and global pharma. Regional context and trusted access.
Our engine updates after every conference, every meeting, every reply. Static databases can't compete.
Every month saved in licensing is a month of patent-protected revenue. Our process compresses quarters into weeks.
Proof in practice
Confidential · EU Specialty Pharma
Deck-aligned deterministic scoring + per-asset web enrichment for a 25+ market specialty BD team.
Read case studyConfidential · US Specialty Pharma
Living shortlist sourced from NMPA, ChinaBio floor coverage, and direct BD network in Shanghai · Beijing · Suzhou.
Read case studyConfidential · Oncology
Out-licensing positioning + EU JCA pre-read + US AMCP outline + curated pharma BD intros — success-only fee.
Read case studyPharma BD looking for curated deal flow. Biotech with a partnerable asset. Investor wanting a window into licensing flow. Tell us which one you are.